Comparison of two hormone replacement regimens--influence on lipoproteins and bone mineral content.
Two hormone replacement therapy regimens were tested in a double-blind clinical trial involving 49 patients. In both cases the oestrogen component was 2 mg oestradiol valerate. This was administered for 21 days and sequentially combined for 10 days with either 0.5 mg norgestrel + (Cyclo-Progynova) or 1 mg cyproterone acetate (SH D 461 A). Each treatment cycle was followed by a 7-day tablet-free period. Both regimens proved to be equally effective in alleviating climacteric complaints. However, the low-density-lipoprotein cholesterol lowering effect of SH D 461 A was found to be superior to that of Cyclo-Progynova. There were no changes in bone mineral content during the one-year treatment period with either combination.
Hirvonen
E
E
Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, Finland.
Elliesen
J
J
Schmidt-Gollwitzer
K
K
D000726:Androgen Antagonists / Q000008:administration & dosage; D015519:Bone Density / Q000187:drug effects*; D003534:Cyproterone / Q000008:administration & dosage / Q000031:analogs & derivatives; D017373:Cyproterone Acetate; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives; D015914:Estrogen Replacement Therapy / Q000379:methods*; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008875:Middle Aged; D009644:Norgestrel / Q000008:administration & dosage
D000726:Androgen Antagonists; D008074:Lipoproteins; D009644:Norgestrel; D017373:Cyproterone Acetate; D004958:Estradiol; D003534:Cyproterone